title: Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases.
abstract: Activation of androgen receptor (AR) may have a role in the development of castration-resistant prostate cancer. Two intracellular tyrosine kinases, Ack1 (activated cdc42-associated kinase) and Src, phosphorylate and enhance AR activity and promote prostate xenograft tumor growth in castrated animals. However, the upstream signals that activate these kinases and lead to AR activation are incompletely characterized. In this study, we investigated AR phosphorylation in response to non-androgen ligand stimulation using phospho-specific antibodies. Treatment of LNCaP and LAPC-4 cells with epidermal growth factor (EGF), heregulin, Gas6 (ligand binding to the Mer receptor tyrosine kinase and activating Ack1 downstream), interleukin (IL)-6 or bombesin stimulated cell proliferation in the absence of androgen. Treatment of LNCaP and LAPC-4 cells with EGF, heregulin or Gas6 induced AR phosphorylation at Tyr-267, whereas IL-6 or bombesin treatment did not. AR phosphorylation at Tyr-534 was induced by treatment with EGF, IL-6 or bombesin, but not by heregulin or Gas6. Small interfering RNA-mediated knockdown of Ack1 or Src showed that Ack1 mediates heregulin- and Gas6-induced AR Tyr-267 phosphorylation, whereas Src mediates Tyr-534 phosphorylation induced by EGF, IL-6 and bombesin. Dasatinib, a Src inhibitor, blocked EGF-induced Tyr-534 phosphorylation. In addition, we showed that dasatinib also inhibited Ack1 kinase. Dasatinib inhibited heregulin-induced Ack1 kinase activity and AR Tyr-267 phosphorylation. In addition, dasatinib inhibited heregulin-induced AR-dependent reporter activity. Dasatinib also inhibited heregulin-induced expression of endogenous AR target genes. Dasatinib inhibited Ack1-dependent colony formation and prostate xenograft tumor growth in castrated mice. Interestingly, Ack1 or Src knockdown or dasatinib did not inhibit EGF-induced AR Tyr-267 phosphorylation or EGF-stimulated AR activity, suggesting the existence of an additional tyrosine kinase that phosphorylates AR at Tyr-267. These data suggest that specific tyrosine kinases phosphorylate AR at distinct sites and that dasatinib may exert antitumor activity in prostate cancer through inhibition of Ack1.
authors.affiliation: UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7295, USA.
authors.forename: Y
authors.initials: Y
authors.lastname: Liu
authors.forename: M
authors.initials: M
authors.lastname: Karaca
authors.forename: Z
authors.initials: Z
authors.lastname: Zhang
authors.forename: D
authors.initials: D
authors.lastname: Gioeli
authors.forename: H S
authors.initials: HS
authors.lastname: Earp
authors.forename: Y E
authors.initials: YE
authors.lastname: Whang
mesh_terms: D059002:Androgen Receptor Antagonists; D000818:Animals; D019556:COS Cells; D048708:Cell Growth Processes / Q000187:drug effects; D045744:Cell Line, Tumor; D002522:Chlorocebus aethiops; D000069439:Dasatinib; D006801:Humans; D015151:Immunoblotting; D008297:Male; D051379:Mice; D010766:Phosphorylation / Q000187:drug effects; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D011743:Pyrimidines / Q000494:pharmacology*; D011944:Receptors, Androgen / Q000235:genetics / Q000378:metabolism; D015398:Signal Transduction; D013844:Thiazoles / Q000494:pharmacology*; D014162:Transfection; D023041:Xenograft Model Antitumor Assays; D019061:src-Family Kinases / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism
chemical_list: C410798:AR protein, human; D059002:Androgen Receptor Antagonists; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D011944:Receptors, Androgen; D013844:Thiazoles; D011505:Protein-Tyrosine Kinases; C403262:TNK2 protein, human; D019061:src-Family Kinases; D000069439:Dasatinib
references.citation: Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):15901-6
references.pmid: 16247015
references.citation: Mol Cell Biol. 2001 Dec;21(24):8385-97
references.pmid: 11713275
references.citation: Cancer Res. 2006 Nov 15;66(22):11047-54
references.pmid: 17108144
references.citation: Br J Cancer. 2006 Jan 30;94(2):318-22
references.pmid: 16421597
references.citation: Oncogene. 2006 Mar 30;25(14):2011-21
references.pmid: 16434977
references.citation: Mol Endocrinol. 2006 Mar;20(3):503-15
references.pmid: 16282370
references.citation: Cancer Res. 2001 Apr 1;61(7):2892-8
references.pmid: 11306464
references.citation: Int J Cancer. 2009 Jan 1;124(1):1-6
references.pmid: 18942061
references.citation: J Biol Chem. 2002 Mar 1;277(9):7076-85
references.pmid: 11751884
references.citation: Cancer Cell. 2006 Oct;10(4):309-19
references.pmid: 17045208
references.citation: J Clin Oncol. 2005 Nov 10;23(32):8253-61
references.pmid: 16278481
references.citation: Cancer Res. 1998 Dec 15;58(24):5718-24
references.pmid: 9865729
references.citation: Curr Cancer Drug Targets. 2007 Sep;7(6):591-604
references.pmid: 17896924
references.citation: Cancer Res. 2005 Apr 15;65(8):3404-9
references.pmid: 15833875
references.citation: Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):11011-6
references.pmid: 16046538
references.citation: Cancer Res. 2005 Nov 15;65(22):10514-23
references.pmid: 16288044
references.citation: J Biol Chem. 2002 Aug 9;277(32):29304-14
references.pmid: 12015328
references.citation: Endocrinology. 2000 Dec;141(12):4698-710
references.pmid: 11108285
references.citation: J Biol Chem. 2008 Jul 25;283(30):20989-1001
references.pmid: 18511414
references.citation: Clin Cancer Res. 2008 Jan 15;14(2):352-9
references.pmid: 18223208
references.citation: Nat Med. 1997 Apr;3(4):402-8
references.pmid: 9095173
references.citation: Cancer Cell. 2004 Nov;6(5):517-27
references.pmid: 15542435
references.citation: Cancer Res. 2009 Jan 1;69(1):151-60
references.pmid: 19117998
references.citation: J Biol Chem. 2002 Oct 11;277(41):38087-94
references.pmid: 12163482
references.citation: Proc Natl Acad Sci U S A. 2006 Jun 27;103(26):9796-801
references.pmid: 16777958
references.citation: Nat Med. 2004 Jan;10(1):33-9
references.pmid: 14702632
references.citation: Cancer Res. 2009 Sep 15;69(18):7402-11
references.pmid: 19706771
references.citation: J Biol Chem. 2009 Dec 11;284(50):34954-63
references.pmid: 19815557
references.citation: J Biol Chem. 2004 Feb 20;279(8):7119-30
references.pmid: 14662770
references.citation: Cancer Res. 2006 Nov 1;66(21):10449-59
references.pmid: 17079466
references.citation: Proc Natl Acad Sci U S A. 2007 May 15;104(20):8438-43
references.pmid: 17494760
references.citation: Clin Cancer Res. 2009 Dec 1;15(23):7421-8
references.pmid: 19920114
references.citation: Clin Cancer Res. 2005 Mar 1;11(5):1704-12
references.pmid: 15755991
references.citation: Cancer Res. 2008 May 1;68(9):3323-33
references.pmid: 18451159